Drug Trial Radar · NCT06143878
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
774
Actual
Start
Jan 17, 2024
Primary completion
Sep 17, 2024
Study completion Jun 1, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Nov 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Conditions
- Plaque Psoriasis
Interventions
JNJ-77242113Drug
JNJ-77242113 will be administered orally.
JNJ-77242113 Matching PlaceboDrug
JNJ-77242113 matching placebo will be administered orally.
DeucravacitinibDrug
Deucravacitinib will be administered orally.
Deucravacitinib Matching PlaceboDrug
Deucravacitinib matching placebo will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16Time frame: Week 16
- Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 16Time frame: Week 16
Locations
164 sites in 13 countries. Site status is shown where the registry gives one.
Medical Dermatology Specialists
Phoenix, Arizona
Center for Dermatology and Plastic Surgery
Scottsdale, Arizona
Johnson Dermatology
Fort Smith, Arkansas
First OC Dermatology
Fountain Valley, California
Center for Dermatology Clinical Research
Fremont, California
Integrative Skin Science and Research
Sacramento, California
Southern California Dermatology
Santa Ana, California
Clinical Science Institute
Santa Monica, California
Driven Research LLC
Miami, Florida
Ziaderm Research LLC
North Miami Beach, Florida
Renstar Medical Research
Ocala, Florida
Forcare Clinical Research Inc
Tampa, Florida
Hamilton Research LLC
Alpharetta, Georgia
Skin Care Physicians of Georgia
Macon, Georgia
DeNova Research
Chicago, Illinois
Arlington Dermatology
Rolling Meadows, Illinois
Endeavor Health
Skokie, Illinois
Dundee Dermatology
West Dundee, Illinois
Dawes Fretzin Clinical Research Group LLC
Indianapolis, Indiana
Indiana Clinical Trial Center
Plainfield, Indiana
Dermatology Specialists
Louisville, Kentucky
Dermatology and Advanced Aesthetics
Lake Charles, Louisiana
Tufts Medical Center
Boston, Massachusetts
David Fivenson MD, Dermatology
Ann Arbor, Michigan
Michigan Center of Medical Research
Clarkston, Michigan
Henry Ford Medical Center
Detroit, Michigan
Hamzavi Dermatology
Fort Gratiot, Michigan
MediSearch Clinical Trials
Saint Joseph, Missouri
Skin Specialists
Omaha, Nebraska
Fife Dermatology
Las Vegas, Nevada
StracSkin
Portsmouth, New Hampshire
Schweiger Dermatology Group
East Windsor, New Jersey
Schweiger Dermatology Group 1
Hackensack, New Jersey
Derm Research Center of New York, Inc.
Stony Brook, New York
Wilmington Dermatology Center
Wilmington, North Carolina
Oakview Dermatology
Athens, Ohio
Optima Research
Boardman, Ohio
Central Sooner Research
Oklahoma City, Oklahoma
Oregon Medical Research Center
Portland, Oregon
Health Concepts
Rapid City, South Dakota
Showing 40 of 164 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.